Roivant Sciences is a unique biopharmaceutical company focused on realizing the full value of promising drug candidates to improve the lives of patients and their families. It is Roivant’s mission to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Our world-class drug development experts work across multiple clinical and functional areas. Roivant delivers R&D solutions to our partners in the biopharmaceutical industry, helping them unlock value from their pipelines by completing the clinical development of promising drug candidates in the most efficient way.
Roivant focuses on developing and commercializing novel therapies through subsidiary ‘Vants’. These include Axovant (neurology), Myovant (women’s health and endocrine diseases), Dermavant (dermatology), Enzyvant (rare diseases), Urovant (urology), and Datavant (artificial intelligence). The company is headquartered in Basel, Switzerland, with operations in the United States in New York, NY, Cambridge, MA, Durham, NC, and San Francisco, CA.